News CRISPR Therapeutics plans Nasdaq launch CRISPR Therapeutics, the Swiss genome-editing company, has filed for a $90 million initial public offering.
News Fulcrum Therapeutics promises new drugs for rare disorders Company launched following $55 million series A funding round.
News Caribou gains $30m funding for CRISPR-Cas platform Genetic engineering specialist Caribou Biosciences has secured $30 million in a series B funding round.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
